Which patient groups can be treated with long-acting injectables?

Long-acting injectables (LAIs) are often used in patients with chronic schizophrenia who have frequent relapses accompanied by marked social and occupational disabilities,¹ including patients who have been non-adherent to other antipsychotics (APs).²

At the American Psychiatric Association Annual Meeting in 2022, Dr. Jose Rubio (Assistant Professor of Psychiatry at the Zucker School of Medicine at Hofstra/Northwell, New York) discussed the utilization of LAIs in other patient groups, including those with first-episode psychosis (FEP).